Semaglutide Associated With Reduced Asthma Attacks and COPD Flare-ups in Study
Source Summary
Research presented at the European Respiratory Society Congress in Barcelona found that semaglutide, a diabetes and weight-loss injection, can reduce asthma attacks by up to 40% and COPD flare-ups by 20%. The study was led by Chloe Bloom, clinical associate professor in respiratory epidemiology at Imperial College London's National Heart & Lung Institute, and presented by Dr. Bohee Lee.
Why it matters
The findings suggest semaglutide may offer therapeutic benefits beyond weight loss and diabetes management, potentially providing a new treatment avenue for patients with chronic respiratory conditions.
